High Times
Home > Boards > US OTC > Biotechs >

Innovus Pharmaceuticals, Inc. (INNV)

INNV RSS Feed
Add INNV Price Alert      Hide Sticky   Hide Intro
Moderator: Drugdoctor, kkpennies, Honeycomb777, florida investor, NewTrader2017
Search This Board: 
Last Post: 10/21/2018 4:53:44 PM - Followers: 174 - Board type: Free - Posts Today: 28

INNOVUS PHARMA (INNV)  

*32 Products in USA / 12 Internationally*

(latest Corporate Presentation dated 8/31/18)

 www.innovuspharma.com (Website)

www.fluticare.com
www.allervarx.com
  www.apeaz.com
 www.zestra.com
 www.ejectdelay.com
 www.myvesele.com
www.urivarx.com
 www.sensumplus.com
 www.myandroferti.com
 www.beyondhumantestosterone.com
www.getbeyondhuman.com
 www.trybeyondhuman.com
 www.recalmax.com
 www.prostagorx.com
 
www.xyralid.com
 
https://twitter.com/innovuspharma



https://innovuspharma.com/our-products/
* shareholders, please consider purchasing product(s)




 2018 Net Revenue Guidance of ~$23M (Up from $8.8M in 2017)


 
.

Innovus Pharma Launches FlutiCare™ OTC Nasal Spray Allergy Relief in the U.S. Press Release |11/14/2017

Innovus Pharmaceuticals, Inc. (“Innovus Pharma” or the “Company”) (OTCQB Venture Market: INNV), an emerging commercial-stage pharmaceutical company that delivers safe, innovative and effective over-the-counter (“OTC”) medicine and consumer care products to improve men’s and women's health and respiratory diseases, today announced that it has officially launched FlutiCare™ OTC in the U.S. FlutiCare™ contains the most prescribed nasal steroid active pharmaceutical ingredient (“API”) and form for nasal allergy relief over the last 7 years. The Company is launching FlutiCare™ in over 10,000 independent pharmacies, direct and through Amerisource Bergen and McKesson, via its Beyond Human® extensive print media platform and through its extensive online channels and distributors, including its own website, Amazon, and Walmart online stores. As a second phase of its launch, Innovus Pharma will launch FlutiCare™ to large retail stores.

FlutiCare™ will be available OTC with the same prescription strength and same delivery method as Flonase®* and ClariSpray®*. The Company currently believes that FlutiCare™ will be the most affordable fluticasone propionate nasal spray on the market and is now available in one dose, a 30 Day (120 Sprays) treatment and is the only one providing an monthly autoship plan.

“We are very excited to launch FlutiCare™ OTC and provide all patients with allergy relief,” stated Dr. Bassam Damaj, President and Chief Executive Officer of Innovus Pharma. “FlutiCare™ traces its roots as the most prescribed Rx 24-hour nasal allergy spray API and form in the U.S. over the past 7 years by a factor of over 10 to 1,” he continued.

FlutiCare™ was approved by the U.S. Food and Drug Administration (“FDA”) for OTC availability through Innovus Pharma’s partner’s approved abbreviated new drug application (“ANDA”) No. 207957. FlutiCare™ allergy relief joins the growing Innovus Pharma product family, offering a burgeoning portfolio of non-prescription medicine and consumer care supplements to consumers.

FlutiCare™ becomes the Company’s second available allergy relief product along with AllerVarx™, a patented dietary supplement formulated to provide relief during the allergy season, already on the market.

In addition, the Company, pending FDA’s guidance, plans to move forward with a fluticasone kit for nasal allergy containing FlutiCare™ and our upcoming saline nasal spray NasaVa™.

About FlutiCare™

FlutiCare™ is a nasal spray, which provides 50 micrograms of fluticasone propionate (“USP”) per spray, a nasal corticosteroid that provides 24-hour temporary relief of seasonal and perennial nasal allergy symptoms. FlutiCare™ can be used to relieve both indoor and outdoor nasal allergy symptoms caused by pollen, dust, animal dander, and other indoor and outdoor allergens. Nasal allergy symptoms include, nasal congestion, runny nose, sneezing, itchy nose, etc.
 

** FlutiCare™ contains the nasal steroid API that is physician recommended and consumer preferred **

  • #1 form used by patients;
    #1 nasal steroid active prescribed by physicians;
    Familiar to patients, comfort of a known & trusted medicine;
    Engrained in patients’ allergy management; and
    Effective and safe.

 

https://www.youtube.com/watch?v=fHQBewvDK6M


 

Company Profile:

Headquartered in San Diego, Innovus Pharma is an emerging leader in OTC and consumer products for men's and women's health and vitality. The Company generates revenues from its lead products (a) BTH® Testosterone Booster, (b) BTH® Human Growth Agent, (c) Zestra® for female arousal and (d) EjectDelay® for premature ejaculation and has an additional five marketed products in this space, including (e) Sensum® for the indication of reduced penile sensitivity, (for sales outside the U.S. only), (f) Zestra Glide®, (g)Vesele® for promoting sexual and cognitive health, (i) Androferti® (in the US and Canada) to support overall male reproductive health and sperm quality, (j) BTH Vision Formula, (k) BTH Blood Sugar, among others and eventually FlutiCare™ OTC for Allergic Rhinitis, if its ANDA is approved by the U.S. FDA.



Business Summary:

Innovus Pharmaceuticals, Inc., a pharmaceutical company, engages in the commercialization, licensing, and development of non-prescription medicine and consumer care products in the United States. Its products include Zestra, a non-medicated patented consumer care product to enhance desire, arousal, and satisfaction in women; EjectDelay, an over-the-counter monograph-compliant benzocaine-based topical gel for treating premature ejaculation; Sensum+, a non-medicated consumer care cream that enhances penile sensitivity; Zestra Glide, a high viscosity and low osmolality water-based lubricant; Vesele, a proprietary oral dietary supplement to enhance nitric oxide beneficial clinical effects on sexual functions and brain health; and Androferti to support overall male reproductive health and sperm quality. The company?s pipeline products includes FlutiCare, an over the counter drug for Rhinitis; Urocis for urinary tract infection; and AndroVit, a proprietary supplement to support overall prostate and male sexual health. The company markets and sells its products through commercial partners to primary care physicians, urologists, gynecologists, and therapists; and directly to consumers through online channels, retailers, and wholesalers. Innovus Pharmaceuticals, Inc. was incorporated in 2011 and is based in San Diego, California.



Bassam Damaj, Ph.D.
President and Chief Executive Officer:


Dr. Bassam Damaj was appointed to serve as our President and Chief Executive Officer in January 2013. Prior to joining Innovus Pharma, Dr. Damaj served as President and Chief Executive Officer of Apricus Biosciences, Inc. (NASDAQ: APRI), a specialty pharmaceutical company, from December 2009 until November 2012. At Apricus Bio, Dr. Damaj was responsible for the approval of its lead drug Vitaros, a treatment for erectile dysfunction. Dr. Damaj also signed multimillion dollar partnerships between Apricus Bio and leading pharmaceutical companies such as Abbott, Novartis-Sandoz and Takeda. Before Apricus Bio, Dr. Damaj was a co-founder of Bio-Quant, Inc. and served as the Chief Executive Officer and Chief Scientific Officer and a Director of Bio-Quant's board of directors from its inception in June 2000 until its acquisition by Apricus Biosciences in December 2009. In addition, Dr. Damaj was the founder, Chairman, President and Chief Executive Officer of R&D Healthcare, and the co-founder of Celltek Biotechnologies. He also served as a Director of the Board of Directors at CreAgri, Inc. and was a Member of the Scientific Advisory Board of MicroIslet, Inc. He is the author of the Immunological Reagents and Solutions reference book, the inventor of many patents and author of numerous peer reviewed scientific publications. Dr. Damaj won a US Congressional award for the Anthrax Multiplex Diagnostic Test in 2003. Dr. Damaj holds a Ph.D. degree in Immunology/Microbiology from Laval University and completed a postdoctoral fellowship in molecular oncology from McGill University.
 



Who are the major players at Innovus Pharma?
 

Management Team

 

* Bassam Damaj, Ph.D.

President and Chief Executive Officer

Prior to joining Innovus Pharma, Bassam Damaj served as President and Chief Executive Officer of Apricus Biosciences, Inc. (NASDAQ: APRI), a specialty pharmaceutical company where he was responsible for the approval of its lead drug Vitaros™, a treatment for erectile dysfunction. Damaj also signed multimillion-dollar partnerships between Apricus Bio and leading pharmaceutical companies such as Abbott, Novartis-Sandoz and Takeda. He was also a Co-founder of Bio-Quant, Inc., serving as the Chief Executive Officer/Chief Scientific Officer and managing the board of directors from its inception in June 2000 until its 2009 acquisition by Apricus Biosciences. In addition, Damaj was the Founder/Chairman/President/Chief Executive Officer of R&D Healthcare, and the Co-Founder of Celltek Biotechnologies. He also served as a Director of the Board of Directors at CreAgri, Inc. and was partof the Scientific Advisory Board of MicroIslet, Inc. He authored Immunological Reagents and Solutions: A Laboratory Handbook (2000) and won a U.S. Congressional Award for the Anthrax Multiplex Diagnostic Test in 2003. Damaj holds a Ph.D. degree in Immunology/Microbiology from Laval University and completed a postdoctoral fellowship in Molecular Oncology at McGill University.

 

* Randy Berholtz, M.B.A./J.D.

Executive Vice President, Corporate Development and General Counsel

In addition to his responsibilities as Executive Vice President and Corporate Development and General Counsel, Randy Berholtz is also the Secretary of the company. He was the founding partner of the Sorrento Valley Law Group and is the former Executive Vice President and General Counsel and Secretary of Apricus Biosciences, Inc. (NASDAQ: APRI), a specialty pharmaceutical company. Prior to that time, he was the Vice President, General Counsel and Secretary of ACON Laboratories, Inc., a group of Chinese and U.S. life sciences companies. He has also been the Chief Operating Officer and General Counsel of IngleWood Ventures, L.P., a life sciences venture capital company, and the Interim General Counsel and Secretary of Nanogen, Inc. (NASDAQ: NGEN), a genomics tools company. He has also been an attorney with the law firms, including Heller Ehrman LLP, Cooley LLP, Kirkpatrick & Lockhart LLP (now K&L Gates LLP) and Cravath, Swaine & Moore LLP. He has a Bachelor of Arts degree from Cornell University, a Master of Arts degree from Oxford University (he was a Rhodes Scholar), and a Juris Doctor degree from Yale Law School - where he was a Senior Editor of the Yale Law Journal - and an MBA from the University of San Diego School of Business.
 

* Ryan Selhorn, CPA

Vice President, Chief Financial Officer

Ryan has served as our Vice President and Chief Financial Officer since April 27, 2018. From July 2013 to April 2018, he was the Chief Financial Officer and Chief Accounting Officer of Signature Analytics, an outsourced finance and accounting firm. From October 2003 to July 2013, he was an Audit Senior Manager with Grant Thornton LLP, a financial accounting firm. Mr. Selhorn has significant experience with venture financings, public equity offerings, public debt offerings, mergers and acquisitions, interaction with the SEC and PCAOB, and implementation and monitoring compliance with the requirements of the Sarbanes-Oxley Act. Additionally, Mr. Selhorn has participated in several financial due diligence processes for acquisitions and capital financings. Mr. Selhorn received his B.S. in Accounting and Finance from Georgetown University, McDonough School of Business, and he is a certified public accountant in California.
 

* Christopher Stella

Vice President of Operations

Christopher Stella has served as our Vice President of Operations since June 2018. From February 2014 to June 2018 he was President and CEO of Stella Marketing Group, a specialty marketing firm supporting the natural products industry including major public and private health and beauty companies advertising through various direct-to-consumer channels. One of which, Innovus Pharmaceuticals, where he worked directly with management and helped the company exceed revenue targets in both 2017 and 2018. From September 2013 to February 2014, he worked at Nutraclick, a technology-driven health and wellness products company, where he developed the marketing campaigns for their four leading brands found in both major retail outlets such as GNC, Walmart and CVS and popular ecommerce platforms. Mr. Stella received his Bachelor of Economics from the University of Massachusetts (Suma Cum Laude) at Amherst with minors in both Chinese and Finance from the School.


info@innovuspharma.com  (email)


Share Structure:

https://www.otcmarkets.com/stock/INNV/security

Dr. Damaj owns over $23.5M shares.  Novalere owns 25.6M 

Profitability expected exiting 2018 !
- 2018 Projected Revenue of $23M, smashing $8.8M for all of 2017 
- 80%+ Gross Margin
 

 
Products for Purchase:


https://www.ooyess.bargains/

https://innovuspharma.com/our-products/

AMAZON.com


Company Videos:

Innovus Pharma CEO Provides Shareholder Update and Conference Call

http://finance.yahoo.com/news/innovus-pharma-ceo-provides-shareholder-101000536.html

https://www.youtube.com/watch?v=FT9MP0OiMqU

https://www.youtube.com/watch?v=w-FKfRaSj0Y

https://www.youtube.com/watch?v=f7YnqjVLVg0

https://www.youtube.com/watch?v=mqM_dY5Wz3s




Innovus Pharma (INNV): Targeting $3+ Billion Markets With 13 Commercial Products

http://finance.yahoo.com/news/innovus-pharma-innv-targeting-3-150320014.html




Prior Accomplishments:



 

 

 


 


Existing Product Lines @ Innovus Pharma:

https://innovuspharma.com/our-products/

 

- WHAT IS PROSTAGORX™?

PROSTAGORX™ is a clinical strength, multi response prostate supplement, scientifically formulated to effectively maintain good prostate health and help in prevent prostate issues in the future. ProstaGorx™ was developed by top medical doctors and produced in a top-quality, cGMP certified and FDA registered laboratory environment under the most rigorously professional conditions. 

The positive benefits provided by the individual and combination ingredients in ProstaGorx™ have been published in leading medical journals.


- WHAT IS DiabaSens™?______________________________________________________________________________________________________________


DiabaSens™ is a patent-pending advanced, all-natural cream specifically formulated to increase nerve sensation and blood flow in men and women of all ages. Its proprietary blend of key ingredients has been clinically tested to increase sensation of the skin and improve blood flow where applied. DiabaSens™ was developed by top medical researchers and produced in a top-quality, cGMP-certified and FDA-registered laboratory environment under the most rigorously professional conditions. The positive benefits provided by the individual and combination ingredients in DiabaSens™ have been published in leading medical journals.
_____________________________________________________________________________________________________________________________________________________________________















Are you looking to boost your brain health?r
               http://www.recalmax.com/


http://www.urivarx.com/
UriVArx® Bladder Control and Function 

        ** SeeThruEquity has a Target Price of $0.70 for Innovus Pharmaceuticals (INNV)  



http://www.myandroferti.com/  - (In a dozen CVS "pilot" stores)

https://www.myvesele.com/ - (Better SEX, WOW-Z'ers)

https://www.ooyess.bargains/



** Help to get the word out and be a PRODUCT AMBASSADOR for YOUR company   

               
Image result for images of love                    Products ship world-wide - support YOUR company                                                                               

 
 

                                                                                                                                                                                                    

High Times
INNV
Current Price
Volume:
Bid Ask Day's Range
  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
INNV News: Statement of Changes in Beneficial Ownership (4) 10/02/2018 05:00:43 PM
INNV News: Statement of Changes in Beneficial Ownership (4) 10/02/2018 05:00:16 PM
INNV News: Statement of Changes in Beneficial Ownership (4) 10/02/2018 05:00:16 PM
INNV News: Statement of Changes in Beneficial Ownership (4) 10/02/2018 05:00:16 PM
INNV News: Current Report Filing (8-k) 08/31/2018 10:51:00 AM
PlusOneCoin Top Posts
No plusone'd posts yet. Be the first!
PostSubject
#17628  Sticky Note (((BREAKING-NEWS)))-INNOVUS becomes-Cannabis-Stock!-NEW-CBD-SLEEP-AID-for-4th-QUARTER-2018! Drugdoctor 10/18/18 10:34:55 AM
#17551  Sticky Note Innovus Pharma Receives Approval from Amazon(R) to Expand florida investor 10/15/18 08:38:36 AM
#16890  Sticky Note SeeThruEquity Issues Update on Innovus Pharmaceuticals (INNV) and kkpennies 08/21/18 03:28:15 PM
#16050  Sticky Note Willing/wondering about how you can HELP increase our Honeycomb777 07/21/18 11:41:52 AM
#17710   That was something I posted last night. Now Batermere 10/21/18 04:53:43 PM
#17709   Now this is where we are in 100% awaitingamove 10/21/18 04:48:30 PM
#17708   Haha. Only a “semi”? I would be at Batermere 10/21/18 03:49:26 PM
#17707   Man - I would love if B came Honeycomb777 10/21/18 03:47:35 PM
#17706   This find today definitely extends the time ! Honeycomb777 10/21/18 03:42:21 PM
#17705   So the DOOMSAYERS that post ad nauseam about Batermere 10/21/18 03:35:33 PM
#17704   *** Here is the link *** Honeycomb777 10/21/18 03:22:01 PM
#17703   We know that o/s increased exactly 5.3M because Honeycomb777 10/21/18 03:10:11 PM
#17702   Sure thing - let me please crystallize this Honeycomb777 10/21/18 03:05:05 PM
#17701   If that number is correct, how much money Batermere 10/21/18 03:02:02 PM
#17700   I was knockin on the door of somewhere Honeycomb777 10/21/18 02:59:19 PM
#17699   HOORAY!!! Thanks for taking the time to do Batermere 10/21/18 02:58:53 PM
#17698   Ok - so this is what we now know: Honeycomb777 10/21/18 02:56:39 PM
#17697   What was your earlier estimate? This is GOOD NEWS. Batermere 10/21/18 02:53:53 PM
#17696   *****IMPORTANT INFO***** Yeah it's Sunday but this is Honeycomb777 10/21/18 02:45:56 PM
#17695   Again, I ask you - how many of Honeycomb777 10/21/18 02:24:44 PM
#17694   Several ideas/ways to get PPS UP - the Honeycomb777 10/21/18 02:11:41 PM
#17693   THIS. Batermere 10/21/18 02:07:48 PM
#17692   The solution is very very simple, Dr Da florida investor 10/21/18 12:48:41 PM
#17691   I guess we will wait for Q3 ER. Batermere 10/21/18 12:13:42 PM
#17690   Dollar share price at the end of the casinokid11211 10/21/18 11:36:54 AM
#17689   And where is the “under a nickel a Batermere 10/21/18 11:11:02 AM
#17688   Well, I would like to ask what is Honeycomb777 10/21/18 10:33:30 AM
#17687   The only team Damage takes it for is casinokid11211 10/21/18 10:12:10 AM
#17686   If we band together and send out 150 Honeycomb777 10/21/18 09:42:52 AM
#17685   Where is that pre-announcement you were anxiously looking casinokid11211 10/21/18 07:25:16 AM
#17684   Not at all. The cash situation will be Batermere 10/21/18 06:38:13 AM
#17683   Seems to me you are very nervous and casinokid11211 10/21/18 06:24:18 AM
#17682   I'll tell ya Bate...if Bassam can find a Honeycomb777 10/20/18 11:01:56 PM
#17681   It’s truly a WATERSHED moment for INNV. Don’t Batermere 10/20/18 10:38:36 PM
#17680   The raise in pay, the over promising, and Honeycomb777 10/20/18 10:19:53 PM
#17679   I agree on all of your points. We Batermere 10/20/18 10:06:42 PM
#17678   I doubt he will but the easiest way Honeycomb777 10/20/18 09:03:15 PM
#17677   HC: The numbers that scare me are the Batermere 10/20/18 08:48:37 PM
#17676   So what would give us the most bang Honeycomb777 10/20/18 08:17:00 PM
#17675   Some numbers to keep in mind: Honeycomb777 10/20/18 07:55:51 PM
#17674   Ladies and Gentleman, boys and girls, bashers and gi197845 10/20/18 06:24:48 PM
#17673   Fellas over 50, Want to bang like a Honeycomb777 10/20/18 10:50:22 AM
#17672   These are the people that have a say Honeycomb777 10/20/18 10:41:19 AM
#17671   Hey, did Uncle Mike forget where he parked Honeycomb777 10/19/18 06:53:26 PM
#17670   Trust me. Nobody cares what you did with Batermere 10/19/18 06:31:10 PM
#17668   Hopefully Florida the next qtr release can do awaitingamove 10/19/18 11:00:32 AM
#17667   I actually looked at that again this morning Doc... awaitingamove 10/19/18 10:57:48 AM
#17666   Use those 1200 dollars as a down payment florida investor 10/19/18 10:56:25 AM
#17665   Yeah, he’s here again this morning spewing his Batermere 10/19/18 10:40:05 AM
#17664   Like I said Florida...I made 1200.00 yesterday on awaitingamove 10/19/18 10:30:57 AM
#17663   Let's review the EARNINGS REPORT, Shall we? Drugdoctor 10/19/18 10:27:58 AM
#17662   I see .1075 bid and last trade was .11 awaitingamove 10/19/18 10:11:24 AM
#17661   Have you guys seen those bums who sit florida investor 10/19/18 10:07:33 AM
#17660   Bate be fair to your readers...INNV has an awaitingamove 10/19/18 09:44:59 AM
PostSubject